Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVernalis PLC Regulatory News (VER)

  • There is currently no data for VER

Block listing Interim Review

29 Sep 2016 15:00

RNS Number : 2209L
Vernalis PLC
29 September 2016
 

BLOCK LISTING SIX MONTHLY RETURN

 

VERNALIS PLC (the "Company")

 

29 September 2016

 

Vernalis plc (LSE: VER) provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements:

 

Name of applicant:

Vernalis plc

Name of scheme(s):

2007 Long Term Incentive Scheme ("LTIP") and the Savings Related Share Option Plan 2003 ("SAYE")

Period of return (from / to):

From: 29/Mar/2016

To: 29/Sept/2016

Balance of unallotted securities under scheme(s) from previous return:

Total of 2,243,318 Ordinary 1p Shares, split:

· Under LTIP = 2,243,318 Ordinary 1p Shares

· Under SAYE = NIL Ordinary 1p Shares

Plus: The amount by which the block scheme(s) has been increased or application has been made to increase since the date of the last return (if any increase has been applied for):

NIL

Less: Number of securities issued/allotted under scheme(s) during period:

Total of 1,074,958 Ordinary 1p Shares, split:

· Under LTIP = 1,074,958 Ordinary 1p Shares

· Under SAYE = NIL Ordinary 1p Shares

Less: Number of securities forfeited under scheme(s) during period:

767,304

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

Total of 401,056 Ordinary 1p Shares, split:

· Under LTIP = 401,056 Ordinary 1p Shares

· Under SAYE = NIL Ordinary 1p Shares

Number and class of securities originally admitted and the date of admission (including any additions):

No. of Ordinary 1p Shares

Date on which Shares were Admitted to Trading

350,000

6 November 2013, plus

1,049,317

12 May 2014, plus

1,058,184

12 May 2015, plus

1,638,364

30 September 2015

1,189,296

1 April 2016

 

 

-- ends -

 

 

Enquiries:

 

Vernalis plc:

+44 (0) 118 938 0015

Ian Garland, Chief Executive Officer

 

David Mackney, Chief Financial Officer

 

 

Canaccord Genuity Limited (Nominated Adviser):

+44 (0) 20 7523 8000

Dr Julian Feneley

 

Henry Fitzgerald-O'Connor

 

Rupert Winckler

 

Emma Gabriel

 

 

Shore Capital (Joint Broker):

+44 (0) 20 7408 4090

Bidhi Bhoma

 

Toby Gibbs

 

 

FTI Consulting:

+44 (0) 20 3727 1000

Ben Atwell

 

Simon Conway

 

Stephanie Cuthbert

 

 

 

Notes to Editors

 

About Vernalis

Vernalis is a revenue generating, commercial stage pharmaceutical company with significant expertise in drug development. The Group has three approved products: Tuzistra®XR targeting the US prescription cough cold market; MOXATAG®, a once-a-day formulation of the antibiotic, amoxicillin, indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes and frovatriptan for the acute treatment of migraine. It has an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as eight programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier Taisho and Tris.

 

For further information about Vernalis, please visit www.vernalis.com 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BLRLLMMTMBATBBF
Date   Source Headline
10th Oct 201810:18 amRNSStatement re Vernalis Scheme Effective
10th Oct 20187:30 amRNSSuspension - Vernalis plc
9th Oct 201812:03 pmRNSStatement re Court Sanction of Scheme
9th Oct 20187:00 amRNSStatement re Update to Court Sanction Date
8th Oct 20183:07 pmRNSForm 8.3 - Vernalis Plc
3rd Oct 20185:30 pmRNSVernalis
2nd Oct 20183:06 pmRNSResults of Meetings
2nd Oct 20183:00 pmRNSForm 8.3 - Vernalis Plc
1st Oct 20182:57 pmRNSBlock listing Interim Review
20th Sep 20183:12 pmRNSHolding(s) in Company
19th Sep 20182:58 pmRNSForm 8.3 - Vernalis Plc
19th Sep 201810:30 amRNSForm 8.3 - VERNALIS PLC
10th Sep 20189:31 amRNSForm 8.3 - VERNALIS PLC
7th Sep 20189:40 amRNSForm 8.3 - VERNALIS PLC
6th Sep 20187:00 amRNSPublication and Posting of Scheme Document
3rd Sep 201810:11 amRNSForm 8.3 - VERNALIS PLC
31st Aug 201810:09 amRNSForm 8.3 - VERNALIS PLC
29th Aug 20188:33 amRNSForm 8.3 - VERNALIS PLC
23rd Aug 20189:26 amRNSForm 8.3 - VERNALIS PLC
22nd Aug 20186:16 pmRNSHolding(s) in Company
21st Aug 20185:13 pmRNSHolding(s) in Company
21st Aug 201810:08 amRNSForm 8.3 - VERNALIS PLC
21st Aug 20189:27 amRNSForm 8.5 (EPT/RI)
20th Aug 20183:16 pmRNSForm 8.3 - Vernalis Plc
20th Aug 201810:18 amRNSForm 8.3 - VERNALIS PLC
17th Aug 20182:56 pmRNSForm 8.3 - Vernalis Plc
16th Aug 20187:00 amRNSVernalis plc - Board Change
10th Aug 20189:56 amRNSForm 8.5 (EPT/RI)
9th Aug 20181:00 pmRNSRecommended Cash Offer for Vernalis plc
9th Aug 20181:00 pmRNSRecommended offer for Vernalis plc
3rd Jul 20189:50 amRNSForm 8.5 (EPT/RI)
2nd Jul 20184:40 pmRNSSecond Price Monitoring Extn
2nd Jul 20184:35 pmRNSPrice Monitoring Extension
29th Jun 20189:34 amRNSForm 8.5 (EPT/RI)
29th Jun 20187:00 amRNSTotal Voting Rights
20th Jun 20184:40 pmRNSSecond Price Monitoring Extn
20th Jun 20184:35 pmRNSPrice Monitoring Extension
18th Jun 201811:43 amRNSForm 8.5 (EPT/RI)
15th Jun 20185:07 pmRNSRule 2.9 Announcement
14th Jun 20187:00 amRNSTermination of Tris Agreement and Update on FSP
31st May 20187:00 amRNSTotal Voting Rights
29th May 20184:38 pmRNSForm 8.5 (EPT/RI)
25th May 20184:35 pmRNSPrice Monitoring Extension
23rd May 20182:38 pmRNSForm 8.5 (EPT/RI)
18th May 20185:17 pmRNSRule 2.9 Announcement
15th May 20189:07 amRNSForm 8.5 (EPT/RI)
8th May 20183:29 pmRNSForm 8.3 - Vernalis Plc
8th May 20183:14 pmRNSForm 8.3 - Vernalis PLC
8th May 20189:46 amRNSForm 8.5 (EPT/RI) - Vernalis Plc (Amendment)
8th May 20189:34 amRNSForm 8.5 (EPT/RI) Vernalis Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.